Back to top
more

Abbott Laboratories (ABT)

(Real Time Quote from BATS)

$106.49 USD

106.49
3,306,036

-0.78 (-0.73%)

Updated Apr 30, 2024 09:33 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (147 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ABT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Abbott Laboratories [ABT]

Reports for Purchase

Showing records 501 - 520 ( 521 total )

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 501

06/01/2010

Company Report

Pages: 11

EuroPCR Events Suggest ABT Likely to Retain Dominance in DES for Years to Come Share Gains in Balloons Likely to Accelerate, to the Detriment of BSX -- Big Mitral Valve Opportunity Ahead

Provider: WEDBUSH SECURITIES INC.

Analyst: NALBONE P

Price: 25.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 502

05/28/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 503

05/21/2010

Company Report

Pages: 7

A Very Big Step In The Push To Build A Major Branded Generics/Emerging Markets Franchise - 2010 EPS View Intact - Own ABT When The Dust Settles

Provider: WEDBUSH SECURITIES INC.

Analyst: NALBONE P

Price: 25.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 504

05/21/2010

Company Report

Pages: 4

Company Expands Presence in Emerging Markets

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 10.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 505

05/19/2010

Industry Report

Pages: 39

Tour Guide to ASCO 2010-Our Take on the (Many) Abstracts of Interest.

Provider: WEDBUSH SECURITIES INC.

Analyst: BANK P

Price: 75.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 506

04/26/2010

Company Report

Pages: 10

Price: 24.95

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 507

04/22/2010

Company Report

Pages: 8

Solid Q1 Results - Full-Year View Trimmed Due to Reform Tab - We View Stock as High-Quality Value Opportunity

Provider: WEDBUSH SECURITIES INC.

Analyst: NALBONE P

Price: 25.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 508

04/21/2010

Company Report

Pages: 10

Organic Growth Plus Positive Currency Yields Double-Digit Growth in All Major Segments

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 509

04/20/2010

Daily Note

Pages: 22

Med Tech Review and Preview: Big Players Navigate Through Maturing Markets, While BSX Woes

Provider: WEDBUSH SECURITIES INC.

Analyst: NALBONE P

Price: 75.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 510

04/15/2010

Daily Note

Pages: 6

MERGERS & ACQUISITIONS

Provider: WALL STREET ACCESS CORP.

Price: 25.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 511

03/30/2010

Company Report

Pages: 6

FDA Wants More Info Before Approving CERTRIAD No Clue on Potential Timing, But Very Modest Financial Impact A Sign of the Regulatory Times.

Provider: WEDBUSH SECURITIES INC.

Analyst: NALBONE P

Price: 25.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 512

03/09/2010

Company Report

Pages: 7

ACCORD Results Should Not Rattle Investors Much Longer - Meanwhile, EVEREST II, Latest ABSORB Data Likely to Boost Confidence in Vascular Opportunity -- Expect Stock to Gain Momentum After ACC

Provider: WEDBUSH SECURITIES INC.

Analyst: NALBONE P

Price: 25.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 513

02/04/2010

Company Report

Pages: 13

New product launches & strong long term fundamentals paint robust outlook.Better than industry average growth prospects justify stock’s moderate premium to Global Pharma peers.

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 50.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Medical - Drugs

Record: 514

02/01/2010

Company Report

Pages: 11

Price: 24.95

Company: Abbott Laboratories

Industry: Medical - Drugs

Record: 515

01/28/2010

Company Report

Pages: 10

Long-term Growth from Many Sources

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Medical - Drugs

Record: 516

01/28/2010

Company Report

Pages: 7

Solid Q4 Performance, On-Target 2010 Guidance, and Lots of Moving Parts to Sort Through as a New Year Begins

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Medical - Drugs

Record: 517

01/22/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 10.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Medical - Drugs

Record: 518

01/20/2010

Daily Note

Pages: 17

December Quarter Review and 2010 Preview: The Graying of the Cardiac Devices Market

Provider: WEDBUSH SECURITIES INC.

Price: 50.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Medical - Drugs

Record: 519

01/15/2010

Industry Report

Pages: 5

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 10.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Medical - Drugs

Record: 520

01/08/2010

Company Report

Pages: 7

A Very Well-Timed Approval for XIENCE in Japan - Launch Likely to Get a Big Lift from Lancet Article (COMPARE), Pending NEJM Article (SPIRIT IV)

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party